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Tuberculosis (TB) is the leading cause of death from an infectious pathogen worldwide
and the most prevalent opportunistic infection in people living with HIV. Isoniazid preven-
tive therapy (IPT) reduces the incidence of active TB and reduces morbidity and mortality
in HIV-infected patients independently of antiretroviral therapy. However, treatment of
latent or active TB is lengthy and inter-patient variability in pharmacokinetics and adher-
ence common. Current methods of assessing adherence to TB treatment using drug lev-
els in plasma or urine assess short-term exposure and pose logistical challenges. Drug
concentrations in hair assess long-term exposure and have demonstrated pharmacody-
namic relevance in HIV.
Methods
A large hair sample from a patient with active TB was obtained for assay development.
Methods to pulverize hair and extract isoniazid were optimized and then the drug detected
by liquid chromatography/ tandem mass spectrometry (LC/MS-MS). The method was vali-
dated for specificity, accuracy, precision, recovery, linearity and stability to establish the
assay’s suitability for therapeutic drug monitoring (TDM). Hair samples from patients on
directly-observe isoniazid-based latent or active TB therapy from the San Francisco Depart-
ment of Public Health TB clinic were then tested.
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Results
Our LC/MS-MS-based assay detected isoniazid in quantities as low as 0.02ng/mg using
10–25 strands hair. Concentrations in spiked samples demonstrated linearity from 0.05–
50ng/mg. Assay precision and accuracy for spiked quality-control samples were high, with
an overall recovery rate of 79.5%. In 18 patients with latent or active TB on treatment, isoni-
azid was detected across a wide linear dynamic range.
Conclusions
An LC-MS/MS-based assay to quantify isoniazid levels in hair with performance character-
istics suitable for TDM was developed and validated. Hair concentrations of isoniazid
assess long-term exposure and may be useful for monitoring adherence to latent or active
TB treatment in the setting of HIV.
Introduction
Tuberculosis (TB) remains one of the greatest threats to public health today, surpassing HIV as
the leading cause of death from an infectious pathogen in 2015 [1]. TB is also the leading cause
of death among HIV-infected individuals worldwide and the provision of isoniazid preventive
therapy (IPT) to those with HIV reduces the risk of HIV-associated illness or death signifi-
cantly and independently of antiretroviral therapy (ART) [2, 3]. Yet, controlling the TB epi-
demic has been threatened by high rates of treatment default and failure. The requirement of
prolonged treatment courses for latent and active TB threatens sustained adherence, and con-
siderable inter-patient pharmacokinetic (PK) variability for commonly-used TB medications,
including isoniazid (INH), may contribute to the emergence of resistance [4, 5] and adverse
treatment outcomes.
Given the importance of monitoring adherence and exposure to anti-TB medications dur-
ing the treatment of both latent TB infection (LTBI) and active disease, the routine incorpo-
ration of therapeutic drug monitoring (TDM), where drug levels are monitored in a biomatrix,
has been recommended[6]. Pharmacologic exposure measures are important in disease states
such as TB, where no accurate individual-level surrogate biomarkers for assessing early preven-
tative or curative responses exist. Ensuring optimal TB medication adherence/exposure is even
more critical in HIV-infected patients, in whom the risk of low drug exposure, drug-drug inter-
actions, adherence difficulties, and acquired drug resistance is highest [7–10]. TDM using sin-
gle or multiple plasma levels indicates only recent exposure and requires phlebotomy, a cold
chain for storage and shipment, and patient accuracy in reporting the time of the last dose con-
sumed. Monitoring urine concentrations of anti-TB medications holds promise, but also
assesses drug or metabolite exposure over short periods of time and requires a cold chain.
TDM via drug levels in dried blood spot (DBS) avoids logistical issues associated with plasma
assays [11], although instability of INH in DBS, variability in the sample method, and lack of
assay standardization can introduce error [12]. A low-cost, noninvasive, easily-collected, alter-
native method for assessing adherence and exposure to TB drugs among HIV-infected and
uninfected patients could provide an important clinical tool for both LTBI and active TB
treatment.
Levels of medications in hair reflect drug uptake from the systemic circulation over weeks to
months [13] and surpass single plasma assays or DBS monitoring in reflecting long-term
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exposure. Hair collection is noninvasive and does not require specific skills, sterile equipment,
specialized storage conditions, a cold chain, or biohazardous precautions. Our group has culti-
vated expertise in monitoring antiretroviral (ARV) exposure during HIV treatment and pre-
vention via assaying ARV concentrations in small-volume hair samples [14–26]. We have
found that hair levels of ARVs correlate strongly with areas-under-the-plasma concentration-
time-curves (AUCs) from intensive PK studies [20], are the strongest independent predictor of
treatment outcomes in HIV disease [15–18, 23, 24], and display linear relationships with dose
[21]. Monitoring anti-TB drugs in hair could provide a long-term measure of exposure with
feasibility advantages in the resource-poor setting. We describe here the development and vali-
dation of an assay to measure isoniazid in small hair samples using liquid chromatography-
tandem mass spectrometry (LC-MS/MS).
Materials and Methods
Shaved head sample for assay development
In order to develop and optimize laboratory assays for measuring anti-TB drugs in hair, we
require large volumes of hair and therefore shave the heads of patients on LTBI or active TB
treatment. We recruited one HIV-infected patient from San Francisco General Hospital with
active pulmonary TB who was on INH, rifampin, pyrazinamide, and ethambutol for initial
assay development. Of note, this patient was also on dolutegravir (dosed twice daily), tenofovir
disoproxil fumarate (TDF) and emtricitabine (FTC) for the simultaneous treatment of his HIV
infection. The protocol and written consent form for shaving the heads of individuals on anti-
TB therapy were approved by the UCSF Committee on Human Research (UCSF CHR #14–
14609) prior to recruitment. Upon obtaining written informed consent, we refer patients to a
barber employed by the study who cuts each person’s scalp hair down to a total length of
approximately 1 inch (~2.5 centimeters (cm)) and then completely shaves off the remaining
hair for the assay optimization work.
Cut hair samples for assay validation
We then recruited 18 patients who were on INH either for LTBI (n = 7) or for active TB treat-
ment (n = 11) from the San Francisco Department of Public Health TB Clinic for the collection
of 200–300 strands of hair (~20–30 mg) for assay validation. Of the 11 patients on active TB
therapy, all were on directly observed therapy (DOT). Of the 7 patients treated for LTBI, 2
were on daily INH (300mg) and not on DOT; five were on intermittent once weekly LTBI
treatment (INH 900mg and rifapentine once weekly) and were all on DOT. All patients pro-
vided written informed consent and the protocol was approved by the UCSF Committee on
Human Research (UCSF CHR #14–14609) prior to the collection of smaller hair samples.
Hair sample collection has been previously described [22]. Briefly, a small thatch of hair is
isolated from the occipital region of the scalp and cut as close to the scalp as possible. The cut
thatch of hair is placed inside a piece of tin foil with a patient study ID label taping the distal
end of the hair thatch (furthest away from the scalp) to the foil to mark directionality. The hair
sample is then stored in a plastic bag at room temperature and in a dark place prior to analysis.
Of note, we collected 200–300 strands of hair for assay validation in this study, but required
only 10% of that (10–25 strands) for analysis; the remainder of each hair sample was stored for
repeat runs and future experiments.
Table 1 describes the characteristics of the one individual in the shaved head study (patient
SH-001) and the 18 individuals with active or latent TB from whom small samples of hair were
cut. Hair collection from these individuals was conducted from July-September 2015.
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Methods to analyze INH in hair
Chemicals. We purchased reference standards for isoniazid (98% chemical purity) and
isoniazid-d4 (internal standard, 98% chemical purity, 98.4% isotopic purity) from Toronto
Research Chemicals (Ontario, Canada). We obtained analytical grade water, methanol, and
acetonitrile from Honeywell Burdick and Jackson (Muskegon, MI). We prepared stock solu-
tions of the standard and internal standard at 1 milligram (mg)/milliliter (mL), aliquoted to
1mL portions in amber vials and stored at -80°C. All calibration standards, ranging in concen-
tration from 0.05 to 50 nanograms (ng)/mg hair, were prepared from the stock solution.
Isoniazid Analysis. We used an Agilent LC 1260 (Sta. Cruz, CA) equipped with a binary
pump and an AB Sciex API 5500 (Foster City, CA) as the analytical platform for our method.
We pulverized human hair samples (2 mg, about 10–25 one centimeter strands) using an
Omni Bead Ruptor1 homogenizer (Kennesaw, GA) and extracted the pulverized hair samples
in methanol. The extracts (10 microliter (uL)) were then separated on a Phenomenex Synergi
Polar-RP (2.1 x 100 mm, 2.5 μm particle size) column (Torrance, CA) using water with 0.2%
(v/v) formic acid as mobile phase at a flow rate of 0.4 mL/min. We monitored INH at multiple
Table 1. Characteristics of patients on INH recruited July-September 2015 for INHmeasurements in small hair samples.
Sample
ID










SH-001 51 M African
American
Active Yes Y 8 300mg Rifampin,
TB-003 41 F Hispanic Active Yes N 2 300 Rifampin, Ethambutol
TB-004 40 M Asian/Filipino Latent Yes N 2 900 per week Rifapentine once weekly
TB-005 56 M Asian/Filipino Active Yes N 7.5 300 Rifampin, Ethambutol
TB-006 53 M Asian Active Yes N 6.5 300 Rifampin, Ethambutol,
Pyrazinamide
TB-007 3 M Asian Active Yes N 4 200 Rifampin, Ethambutol,
Pyrazinamide
TB-008 66 M Caucasian Active Yes N 2.5 300 Rifampin, Ethambutol,
Pyrazinamide
TB-009 47 M Caucasian Active Yes Y 4.5 300 Rifampin, Ethambutol,
Pyrazinamide
TB-010 34 F Asian/
Chinese
Active Yes N 3.5 300 Rifampin, Ethambutol,
Pyrazinamide
TB-011 76 F Asian Active Yes N 9 300 Rifampin, Ethambutol,
Pyrazinamide
TB-012 55 M Asian Active Yes N 4 300 Rifampin, Ethambutol,
Pyrazinamide
TB-013 46 F Asian/
Mongolian
Latent No N 2 300 Rifampin
TB-014 66 M Asian/
Chinese
Active Yes N 4 300 Pyrazinamide,
Ethambutol
TB-015 18 M Hispanic Latent No Never
tested
4.5 300 None
TB-016 75 M Asian Latent Yes N 1 900 per week Rifapentine once weekly
TB-017 26 M Asian Active Yes N 1.5 300 Rifampin, Ethambutol,
Pyrazinamide
TB-018 54 M Hispanic Latent Yes N 1 900 per week Rifapentine once weekly
TB-020 25 M Hispanic Latent Yes N 2 900 per week Rifapentine once weekly
TB-021 15 F Filipina Latent Yes N 2.5 900 per week Rifapentine once weekly
doi:10.1371/journal.pone.0155887.t001
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reaction mode using an electrospray ion source operated in positive polarity. We used two
transitions to monitor INH: 138.1> 79.0 m/z (quantifier) and 138.1>120.9 m/z (qualifier).
We analyzed the data obtained from our LC-MS/MS runs using AB Sciex Analyst 1.6 and
AB Sciex MultiQuant 2.1 software packages (Foster City, CA). We identified and confirmed
INH based on its retention time and the peak area ratio between its two transitions. We quanti-
fied INH in hair samples by isotope dilution method using INH-d4 as internal standard. We
monitored INH-d4 using the transition 142.1> 82.9 m/z.
Method validation
To validate our method, we assessed its performance in terms of its specificity, precision, accu-
racy, linearity, recovery and stability. To assess specificity, we analyzed nine different lots of
hair samples from subjects not on INH to determine if there are endogenous components of
hair that could interfere with INH detection. We conducted precision, accuracy, and recovery
studies by running three different concentrations of INH (low = 0.2 ng/mg, medium = 2.0 ng/
mg, high = 20.0 ng/mg) spiked into a matrix blank. We verified that hair derived from subjects
not on INH exhibited no INH signal as matrix blank. For within run precision, we ran five
samples of each concentration within a batch while three batches of five samples of each con-
centration were run over three separate days to calculate between-run precision. Accuracy and
recovery for each sample run were calculated along with precision.
We performed linearity studies by running the calibration standards (0.05–50 ng/mg) five
separate times over separate days and assessing the linear regression coefficient of the calibra-
tion plot obtained in each run. We assessed the stability of the extracts obtained from blank
hair samples spiked with different levels of INH (low, medium, high) during incubation at
three different temperatures (25°C, 4°C and -80°C) for 21 days. We checked the level of INH in
each extract at days 1, 2, 3, 7, 10, 14, 17 and 21 or until at least one of the extracts at a certain
incubation temperature was<80% its initial value.
INH measurement in patient samples
We used the above-described assay to measure INH in hair samples from 18 recruited patients
on INH. Duplicate samples of each patient were also run.
Results
INH detection in hair
We successfully developed a rapid and sensitive LC-MS/MS method for detecting and quanti-
fying INH in small hair samples (~2 mg, or 10–25 strands of hair one cm in length). Fig 1
shows the INH peak in a typical LC/MS/MS chromatogram when the drug was extracted from
a patient hair sample (patient TB-007). INH consistently elutes at 1.00 ± 0.05 min in a five-
minute isocratic reversed phase chromatographic separation. INH in hair could be detected as
low as 0.02 ng/mg (limit of detection, LOD) using 2 mg of hair, which is sensitive enough to
detect INH in a range of patient hair samples.
Method validation
No significant endogenous interfering peaks for isoniazid (i.e. peaks with signal to noise
ratio 3) were observed in the chromatograms of the blank human hair samples (Fig 1). The
spiked INH hair samples were linear from 0.05 ng/mg (lower limit of quantification, LLOQ) to
50 ng/mg (upper limit of quantification, ULOQ). The average linear regression coefficient we
established is 0.998 from five separate linearity measurements. The assay precision (% coefficient
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of variation (CV)) and accuracy (relative error (RE)%) for all three levels of spiked hair samples
were<15% (Table 2) while the recovery ranges between 71% and 84% with an over-all recovery
rate of 79.5%. The recovery rates for all three levels of spiked hair samples are reproducible with
precision (%CV)<10% (Table 2). Extracts obtained from spiked hair samples were stable for 1,
3, and 10 days at 25°C, 4°C and -80°C, respectively.
Fig 1. Representative extracted ion chromatogram of INH in small hair samples from a patient on INH
(A) and a patient not taking INH (B).
doi:10.1371/journal.pone.0155887.g001
Table 2. Validation of method accuracy, precision and recovery for the analysis of isoniazid in small hair samples.
Concentration (ng/mg) Precision (%CV) Accuracy (%RE) Recovery
Intraday Interday Intraday Interday Recovery (%) %CV
0.2 9.21 14.75 -4.33 -3.27 84.05 5.55
2.0 5.03 12.32 -4.25 2.27 71.18 7.80
20.0 2.40 7.47 -6.69 -7.20 83.22 8.41
doi:10.1371/journal.pone.0155887.t002
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INH detection in patient hair samples
We detected INH in all patients recruited for our clinical validation study. Fig 2 shows the
range of INH concentrations in 18 small hair samples for patients on either LTBI or active TB
treatment. The mean, geometric mean, and median of INH hair concentrations were 1.77,
1.01, 0.86 ng/mg, respectively.
Discussion
In this study, we describe the development of a novel LC-MS/MS based method to analyze
INH in hair which is sensitive (LLOQ 0.05 ng/mg), precise (%CV<15%), reproducible, and
accurate (RE%<10%). In an accompanying clinical validation study, we were able to isolate,
identify, and quantify INH from small hair samples (~10–25 strands each) from patients on
active or latent TB treatment over a wide linear dynamic range.
To our knowledge, this is the first report on the development and initial validation of a
method for the direct analysis of INH in hair. A previous study reported the analysis of INH
and acetyl-INH in hair samples from 40 patients[27]. However, the study did not report on the
validation of the method and measured INH indirectly as its formyl-INH derivative. Direct
measurement of analytes in biological matrices facilitates faster turn-around time with higher
recovery rates; derivatization adds a step in the assay (prolonging it) where further loss of the
analyte can be incurred. The assay we developed and validated only requires 60 minutes from
hair pulverization to completion of the LC-MS/MS run. Efficient pulverization of the hair sam-
ples via the Omni Bead disruptor1 facilitated the direct extraction of INH via methanol with
minimal incubation time. Methanol also facilitated the precipitation of proteins from pulver-
ized hair. This simple method of extraction is consistent with the most common method of
Fig 2. INH concentrations in 18 hair samples from patients recruited from the San Francisco Department of Public Health TB Clinic (11 with
active TB; 7 with latent TB).
doi:10.1371/journal.pone.0155887.g002
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extracting INH from plasma samples [28–31], which also uses methanol as the agent of protein
precipitation.
INH is a highly polar and basic compound. In reversed-phase (C18, C8) columns it elutes
very close to the void volume even with a highly aqueous mobile phase [29], which may cause
assay interference as other unretained matrix components may co-elute. We were able to
improve the retention of INH using a polar RP column after testing several reversed-phase col-
umns (Phenomenex Kinetex C18, Agilent ZORBAX Extend- C18, Agilent Poroshell 120). The
polar group end cap of the polar RP column facilitated an interaction with INH that allowed
for better retention. A narrow symmetrical peak was consistently obtained for INH within a
narrow range of retention times (0.95–1.05 minute, Fig 1). The method is highly selective for
INH as no peaks were detected in nine different lots of blank hair human samples (Fig 1). Like-
wise, within-run (intraday) and between-run (interday) precision and accuracy established for
the method were all within the acceptance criteria set by the Division of AIDS-Clinical Phar-
macology and Quality Assurance Program [32] based on the Food and Drug Administration
(FDA) guidelines[33].
The standard curve established for the detection of INH in hair in this study has a wider lin-
ear dynamic range (0.05–50 ng/mg vs 0.05–1 ng/mg) than the range previously reported for
formyl-INH and acetyl-INH [27]. The LLOQ established for the assay (0.05 ng/mg) is 2 times
lower than the lowest measured INH level in the patient hair samples (Fig 1) and five times
higher than the assay’s LOD. A wide variation in the concentration of INH in hair was
observed in the 18 patients on active and latent TB treatment in this study. However, all mea-
sured INH levels fell within the linear calibration range. These performance characteristics—
and the ability of the assay to distinguish inter-individual variability in drug levels (which is
expected in the context of real-world adherence- establish the assay’s suitability for TDM.
Although only five patients in our study were receiving a lower cumulative dose of INH
(900mg weekly), our studies suggest a dose-concentration relationship (Fig 2). The wide varia-
tion in INH levels may partially be attributable to pharmacogenetic differences among patients
in their arylamine N-acetyltrasferase (NAT-2) genotype, a polymorphic gene that encodes for
the primary enzyme that metabolizes INH [34]. A previous study that investigated the areas
under the concentration-time curve for plasma INH 12 hours after dosing found a highly sig-
nificant association with the NAT-2 genotype [35]. Future studies by our group will investigate
the relationship between NAT-2 genotype and hair INH levels and the effects of different
washing conditions and temperature exposure on the INH concentrations in hair. Finally, a
more comprehensive investigation of these measures as a marker of adherence/exposure to
latent or active TB treatment in large clinical cohorts of HIV-infected individuals is underway.
Given that INH is a critical, first-line component of both LTBI and active TB regimens, the
ability to monitor this molecule in small hair samples may have potential utility a non-invasive
measure of adherence and exposure. Moreover, the ability to extract INH from only 10–25
strands of hair should enhance acceptability of hair collection. Additional feasibility advantages
to hair monitoring in resource-limited settings (RLS), where rates of TB infection are highest,
include ease of hair collection, transport, and storage. Indeed, we have seen high rates of feasi-
bility and acceptability of hair collection using small samples of hair from patients with HIV
infection in multiple settings [22–24].
Since pharmacologic measures reflect both adherence and pharmacokinetics, concentra-
tions of TB drugs in hair may provide an integrated measure of behavior and biology. Given
the substantial problem with maintaining adherence to prolonged courses of TB treatment,
despite implementation of the WHO Directly Observed Therapy-Short course strategy, in
combination with considerable inter-individual pharmacokinetic variability of commonly-
used TB medications [4, 5], a novel method of TDM that reflects both adherence and PK
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should be helpful to the field. In conclusion, we describe here the development and initial vali-
dation of a novel assay to analyze INH concentrations in small hair samples. Additional studies
to evaluate the predictive utility of hair concentrations of INH on outcomes in HIV-infected
patients on LTBI therapy and active TB treatment are ongoing.
Acknowledgments
The authors would like to thank the San Francisco Department of Public Health Tuberculosis
Clinic staff, in particular Teresa Ampie, and Stephen May, clinical research coordinator, UCSF.
The authors further gratefully acknowledge the contributions of the participants of this study.
Author Contributions
Conceived and designed the experiments: RG. Performed the experiments: AW RG. Analyzed
the data: PB MG JM. Contributed reagents/materials/analysis tools: MG JM CAK ATC. Wrote
the paper: RGMG PB JM ATC CAK AW. Collected hair samples from latent or active TB
patients: JM ATC CAK AW.
References
1. World Health Organization. Global tuberculosis report 2015. Available at http://www.who.int/tb/
publications/global_report/en/. Accessed on January 6, 2016.
2. Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early Antiretrovirals and
Isoniazid Preventive Therapy in Africa. N Engl J Med 2015, 373:808–822. doi: 10.1056/
NEJMoa1507198 PMID: 26193126
3. Hosseinipour M, Bisson G, Miyahara S, Sun X, Moses A, Riviere C, et al. Empiric TB therapy does not
decrease early mortality compared to isoniazid preventive therapy in adults with advanced HIV initiating
ART: results of ACTG A5274 (REMEMBER study). 8th IAS Conference on HIV Pathogenesis, Treat-
ment and Prevention (IAS 2015), Vancouver, Canada, 19–22 July 2015 (abstract MOAB0205LB).
4. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to
noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011, 204:1951–1959.
doi: 10.1093/infdis/jir658 PMID: 22021624
5. Egelund EF, Peloquin CA. Editorial commentary: pharmacokinetic variability and tuberculosis treat-
ment outcomes, including acquired drug resistance. Clin Infect Dis 2012, 55:178–179. doi: 10.1093/cid/
cis366 PMID: 22467672
6. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62:2169–2183.
PMID: 12381217
7. Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update.Clin
Infect Dis 2010, 50:1377–1386. doi: 10.1086/652147 PMID: 20388036
8. Tesfahuneygn G, Medhin G, Legesse M. Adherence to Anti-tuberculosis treatment and treatment out-
comes among tuberculosis patients in Alamata District, northeast Ethiopia. BMC Res Notes 2015,
8:503. doi: 10.1186/s13104-015-1452-x PMID: 26420164
9. Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, et al. Low isoniazid and rifampicin
concentrations in TB/HIV co-infected patients in Uganda. J Int AIDS Soc 2014, 17:19585. doi: 10.7448/
IAS.17.4.19585 PMID: 25394091
10. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin,
ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly
HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009, 48:1685–1694. doi:
10.1086/599040 PMID: 19432554
11. Alffenaar JW. Dried blood spot analysis combined with limited sampling models can advance therapeu-
tic drug monitoring of tuberculosis drugs. J Infect Dis 2012, 205:1765–1766; author reply 1766. doi: 10.
1093/infdis/jis270 PMID: 22459734
12. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring:
methods, assays, and pitfalls. Ther Drug Monit 2009, 31:327–336. doi: 10.1097/FTD.
0b013e31819e91ce PMID: 19349929
13. Beumer J, Bosman I, Maes R. Hair as a biological specimen for therapeutic drug monitoring. In J Clin
Pract 2001, 55:353–357.
Quantifying Isoniazid in Hair Samples as a Marker of Adherence during Tuberculosis Treatment
PLOS ONE | DOI:10.1371/journal.pone.0155887 May 18, 2016 9 / 11
14. Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern
Med 2002, 137:696–697. PMID: 12379072
15. Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair
strongly predict virologic response to treatment. AIDS 2009, 23:471–478. doi: 10.1097/QAD.
0b013e328325a4a9 PMID: 19165084
16. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in
hair is the strongest predictor of outcomes on antiretroviral therapy.Clin Infect Dis 2011, 52:1267–
1275. doi: 10.1093/cid/cir131 PMID: 21507924
17. van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma
or hair concentrations explain second line protease inhibitor failures in a resource-limited setting. J
Acquir Immune Defic Syndr 2011, 56:333–339. doi: 10.1097/QAI.0b013e31820dc0cc PMID:
21239995
18. Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, et al. Nevirapine Concentration in
Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected
Patients. PLoS One 2015, 10:e0129100. doi: 10.1371/journal.pone.0129100 PMID: 26053176
19. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, et al. Hair and Plasma Data Show
That Lopinavir, Ritonavir, and Efavirenz All Transfer FromMother to Infant In Utero, But Only Efavirenz
Transfers via Breastfeeding. J Acquir Immune Defic Syndr 2013, 63:578–584. doi: 10.1097/QAI.
0b013e31829c48ad PMID: 24135775
20. Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymor-
phism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among
HIV-infected women. J Infect Dis 2012, 206:1453–1461. doi: 10.1093/infdis/jis508 PMID: 22927450
21. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, et al. Strong Relationship between Oral
Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-
Exposure Prophylaxis (PrEP). PLoS One 2014, 9:e83736. doi: 10.1371/journal.pone.0083736 PMID:
24421901
22. Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, et al. Antiretroviral concen-
trations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic
Syndr 2014, 66:311–315. doi: 10.1097/QAI.0000000000000154 PMID: 24694932
23. Koss C, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, et al. Hair Concentrations of
Antiretrovirals Predict Viral Suppression in HIV-Infected Pregnant and Breastfeeding Ugandan
Women. AIDS 2015, 29:825–830. doi: 10.1097/QAD.0000000000000619 PMID: 25985404
24. Prasitsuebsai W, Kerr SJ, Truong KH, Ananworanich J, Do VC, Nguyen LV, et al. Using Lopinavir Con-
centrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian
Children. AIDS Res Hum Retroviruses 2015, 31:1009–1014. doi: 10.1089/AID.2015.0111 PMID:
26200586
25. Gandhi M, Yang Q, Bacchetti P, Huang Y. Short communication: A low-cost method for analyzing nevi-
rapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses
2014, 30:25–28. doi: 10.1089/AID.2013.0239 PMID: 24164410
26. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, et al. Strong Correlation Between
Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphos-
phate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophy-
laxis Adherence Monitoring. J Infect Dis 2015, 212:1402–1406. doi: 10.1093/infdis/jiv239 PMID:
25895984
27. Eisenhut M, Thieme D, Schmid D, Fieseler S, Sachs H. Hair Analysis for Determination of Isoniazid
Concentrations and Acetylator Phenotype during Antituberculous Treatment. Tuberc Res Treat 2012,
2012:327027. doi: 10.1155/2012/327027 PMID: 23091716
28. Chen X, Song B, Jiang H, Yu K, Zhong D. A liquid chromatography/tandemmass spectrometry method
for the simultaneous quantification of isoniazid and ethambutol in human plasma. Rapid Commun
Mass Spectrom 2005, 19:2591–2596. PMID: 16106359
29. Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT. Development and validation of a
hydrophilic interaction liquid chromatography-tandemmass spectrometry method for determination of
isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:285–290. doi:
10.1016/j.jchromb.2008.12.024 PMID: 19112051
30. Song SH, Jun SH, Park KU, Yoon Y, Lee JH, Kim JQ, et al. Simultaneous determination of first-line
anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandemmass spec-
trometry. Rapid CommunMass Spectrom 2007, 21:1331–1338. PMID: 17340570
31. Kim HJ, Seo KA, Kim HM, Jeong ES, Ghim JL, Lee SH, et al. Simple and accurate quantitative analysis
of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-
Quantifying Isoniazid in Hair Samples as a Marker of Adherence during Tuberculosis Treatment
PLOS ONE | DOI:10.1371/journal.pone.0155887 May 18, 2016 10 / 11
tandemmass spectrometry. J Pharm Biomed Anal 2015, 102:9–16. doi: 10.1016/j.jpba.2014.08.026
PMID: 25218029
32. DiFrancesco R, Tooley K, Rosenkranz SL, Siminski S, Taylor CR, Pande P, et al. Clinical pharmacol-
ogy quality assurance for HIV and related infectious diseases research.Clin Pharmacol Ther 2013,
93:479–482. doi: 10.1038/clpt.2013.62 PMID: 23588323
33. FDA. Guidance for Industry Bioanalytical Method Validation. 2013. Found at http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf
34. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, et al. The influence of dose
and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacody-
namics of isoniazid. Eur J Clin Pharmacol 2007, 63:633–639. PMID: 17505821
35. Weiner M, BurmanW, Vernon A, Benator D, Peloquin CA, Khan A, et al. Low isoniazid concentrations
and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit
Care Med 2003, 167:1341–1347. PMID: 12531776
Quantifying Isoniazid in Hair Samples as a Marker of Adherence during Tuberculosis Treatment
PLOS ONE | DOI:10.1371/journal.pone.0155887 May 18, 2016 11 / 11
